All In Biotech

Drug Trial Radar · NCT07793942

A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)

A Phase 2, Open-label Clinical Study to Evaluate the Safety and Efficacy of MK-2010 as Monotherapy and in Combination

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

480

Planned (sponsor's estimate)

Start

Oct 21, 2026

Primary completion

Sep 26, 2028

Study completion Jul 28, 2030

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Aug 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat certain types of advanced solid tumors. Solid tumors are cancers mostly in organs and tissues in the body, not in the blood or other fluids. Advanced means the cancer has spread nearby or to other parts in the body and cannot be removed with surgery. In this trial, researchers want to learn if the trial medicine called MK-2010, given alone or with other treatments, can treat advanced solid tumors. MK-2010 is designed to help the immune system fight cancer. The goals of this trial are to learn: * About the safety of MK-2010 as monotherapy and in combinations and if participants tolerate them. Tolerate means participants will receive trial treatment unless they need to stop it due to health problems. * How many participants who receive MK-2010 as monotherapy and in combination respond to treatment. Respond means the cancer gets smaller or goes away.

Conditions

  • Malignant Neoplam
  • Advanced Solid Tumors

Interventions

  • MK-2010Biological

    Administered as an intravenous (IV) infusion.

  • PembrolizumabBiological

    Administered intravenously as 400 mg every 6 weeks.

  • 5-FluorouracilDrug

    Administered intravenously per approved product label.

  • Leucovorin or LevoleucovorinDrug

    Administered intravenously per approved product label.

  • OxaliplatinDrug

    Administered intravenously per approved product label.

  • BelzutifanDrug

    Administered orally as 120 mg daily.

  • GemcitabineDrug

    Administered intravenously per approved product label.

  • CisplatinDrug

    Administered intravenously per approved product label.

  • CarboplatinDrug

    Administered intravenously per approved product label.

  • PaclitaxelDrug

    Administered intravenously per approved product label.

  • Nab-paclitaxelDrug

    Administered intravenously per approved product label.

  • PemetrexedDrug

    Administered intravenously per approved product label.

  • EpinephrineDrug

    Administered per approved product label as rescue medication.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 24 months
  2. Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 24 months
  3. Number of Participants Who Experience Dose-Limiting Toxicity (DLT)Time frame: Up to approximately 28 days
  4. Objective Response Rate (ORR)Time frame: Up to approximately 24 months

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • New Jersey Cancer Care ( Site 7002)

    Belleville, New Jersey · Recruiting

  • START Astera, LLC ( Site 0220)

    East Brunswick, New Jersey · Recruiting

  • Taylor Cancer Research Center ( Site 9500)

    Maumee, Ohio · Recruiting

  • Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8001)

    Eugene, Oregon · Recruiting

  • Princess Margaret Cancer Centre ( Site 1400)

    Toronto, Ontario, Canada · Recruiting

  • Cantonal Hospital St.Gallen ( Site 1100)

    Sankt Gallen, Canton of St. Gallen, Switzerland · Recruiting

  • CHUV (centre hospitalier universitaire vaudois) ( Site 1101)

    Lausanne, Canton of Vaud, Switzerland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.